Purple Biotech Ltd. (PPBT), formerly known as Kitov Pharma Ltd., is an innovative clinical-stage biopharmaceutical company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance in order to disrupt cancer’s growth and progression.
Established in Israel, PPBT is committed to creating life-changing treatments and drugs targeting some of the most stubborn diseases. The company has made significant strides in the development and commercialization of therapeutics to treat major oncological conditions.
Purple Biotech's lead asset, CM24, is a clinical-stage monoclonal antibody developed for the treatment of different types of cancer, including advanced malignancies known to express the CEACAM1 protein, such as melanoma and lung cancer. CM24 is being developed in collaboration with Bristol Myers Squibb, leveraging their extensive experience in immuno-oncology.
At the forefront of drug discovery and clinical research, PPBT also has NT219 in its pipeline, a first-in-class, novel, small molecule designed to overcome cancer drug resistance. The drug is currently undergoing a phase 2 study for its application in treating advanced solid tumors, giving hope that new, more effective treatments could be offered to cancer patients in future.
Part of Purple Biotech’s strength lies in its unique approach to conquering drug resistance, which is a significant problem in treating various aggressive and hard-to-treat cancers. By targeting multiple key signaling pathways, PPBT hopes to halt cancer development at its core.
The company relies on collaboration with other innovative biotech companies and academic institutions to propel its research forward. This strategic approach not only helps the company take advantage of external resources and expertise but also speeds up the development process of its pipeline products.
Purple Biotech is committed to achieving its vision of providing new and effective treatment options to improve patients' lives. Its research and development efforts are in line with its values of innovation, integrity, collaboration, and patient centricity. Overall, PPBT represents an intersection of scientific innovation and a compassionate approach to healthcare, striving to make significant strides in the fight against cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Purple Biotech Ltd. (PPBT) is experiencing significant stock movement due to promising preclinical trial results for its cancer therapy, IM1240, and the CAPTN-13 platform. Despite a price target cut by H.C. Wainwright from $30 to $17 due to limited cash ($6.1M, funding operations only into mid-2027) and high operating expenses, the firm maintains a Buy rating, acknowledging the scientific potential. This creates a volatile situation for traders, driven by catalyst events like potential partnerships or dilutive financing.
Purple Biotech Ltd. (PPBT) reported a significantly improved quarterly loss of $0.00018 per share for Q2 2026, with a net loss of $441,000. The clinical-stage biotechnology company focuses on developing therapies for cancer and continues to advance its programs while managing its cash position. This reflects efforts to reduce losses compared to the previous year as it operates in the oncology space.